Interestingly, TACC3 has been identified as a fusion partner to FGFR3 in bladder cancer, squamous cell lung cancer, oral cancer, head and neck cancer and glioblastoma multiforme [54]. This evidence concerns the gene FGFR3 and lip and oral cavity carcinoma.